Can a blood vessel drug save kidneys in scleroderma crisis?
NCT ID NCT01241383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called bosentan in 16 adults with scleroderma who had a serious kidney complication called scleroderma renal crisis. The goal was to see if bosentan could help protect kidney function and improve survival over 6 months to a year. The drug works by blocking a substance that narrows blood vessels, which may reduce kidney damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA RENAL CRISIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pôle de médecine interne Centre de référence Maladies rares Groupe I Maladies systémiques et maladies auto-immunes rares en particulier Vascularites nécrosantes et les sclérodermies - Hôpital Cochin
Paris, 75014, France